Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Lyra Therapeutics, Inc. (LYRA) had Non-Operating Income/Expense of $4.50M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$1.56M |
|
$-62.68M |
|
-- |
|
$1.56M |
|
$68.68M |
|
$-67.12M |
|
|
Non-Operating Income/Expense |
$4.50M |
$-62.62M |
|
$-62.62M |
|
$-62.68M |
|
$-62.68M |
|
$-62.68M |
|
$-62.68M |
|
$-67.12M |
|
$-70.34M |
|
49.80M |
|
49.80M |
|
$-1.26 |
|
$-1.26 |
|
| Balance Sheet Financials | |
$104.82M |
|
$2.04M |
|
$37.78M |
|
$142.60M |
|
$19.60M |
|
-- |
|
$33.58M |
|
$53.18M |
|
$89.42M |
|
$89.42M |
|
$89.42M |
|
57.22M |
|
| Cash Flow Statement Financials | |
$-63.30M |
|
$-12.58M |
|
$65.69M |
|
$33.94M |
|
$23.75M |
|
$-10.20M |
|
$5.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4308.09% |
|
-4308.09% |
|
-4514.64% |
|
-4019.32% |
|
-4023.11% |
|
$-64.35M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-70.10% |
|
-70.10% |
|
-43.96% |
|
-70.10% |
|
$1.56 |
|
$-1.29 |
|
$-1.27 |
|